BR112018015291A2 - uso de inibidores de histona desacetilase para melhorar imunoterapias - Google Patents
uso de inibidores de histona desacetilase para melhorar imunoterapiasInfo
- Publication number
- BR112018015291A2 BR112018015291A2 BR112018015291A BR112018015291A BR112018015291A2 BR 112018015291 A2 BR112018015291 A2 BR 112018015291A2 BR 112018015291 A BR112018015291 A BR 112018015291A BR 112018015291 A BR112018015291 A BR 112018015291A BR 112018015291 A2 BR112018015291 A2 BR 112018015291A2
- Authority
- BR
- Brazil
- Prior art keywords
- histone deacetylase
- deacetylase inhibitors
- immunotherapies
- inhibitors
- improve
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000003964 Histone deacetylase Human genes 0.000 abstract 1
- 108090000353 Histone deacetylase Proteins 0.000 abstract 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662288121P | 2016-01-28 | 2016-01-28 | |
| PCT/US2017/015389 WO2017132536A1 (en) | 2016-01-28 | 2017-01-27 | Use of histone deacetylase inhibitors for enhancing immunotherapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018015291A2 true BR112018015291A2 (pt) | 2018-12-18 |
Family
ID=58010402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018015291A BR112018015291A2 (pt) | 2016-01-28 | 2017-01-27 | uso de inibidores de histona desacetilase para melhorar imunoterapias |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10813919B2 (enExample) |
| EP (1) | EP3407913A1 (enExample) |
| JP (1) | JP2019503386A (enExample) |
| KR (1) | KR20180104122A (enExample) |
| CN (1) | CN108883179A (enExample) |
| AU (1) | AU2017211383A1 (enExample) |
| BR (1) | BR112018015291A2 (enExample) |
| CA (1) | CA3013047A1 (enExample) |
| IL (1) | IL260765A (enExample) |
| MX (1) | MX2018009247A (enExample) |
| RU (1) | RU2018130831A (enExample) |
| WO (1) | WO2017132536A1 (enExample) |
| ZA (1) | ZA201805066B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| KR102603681B1 (ko) | 2016-12-07 | 2023-11-17 | 아게누스 인코포레이티드 | 항체 및 이의 사용방법 |
| JP7348074B2 (ja) * | 2017-06-04 | 2023-09-20 | ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズ | がん治療に対する個別化応答の予測方法およびそのキット |
| US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
| US12070489B2 (en) | 2018-12-12 | 2024-08-27 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with a cancer therapy in combination with another therapeutic agent |
| TR201900059A2 (tr) * | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
| JP2021511293A (ja) * | 2018-01-12 | 2021-05-06 | ビラクタ セラピューティクス，インク． | 細胞免疫療法で使用されるエピジェネティック修飾因子 |
| KR20210028339A (ko) * | 2019-09-04 | 2021-03-12 | 크리스탈지노믹스(주) | Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물 |
| CN112569360A (zh) * | 2019-09-30 | 2021-03-30 | 中国医学科学院药物研究所 | 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用 |
| EP4385024A4 (en) | 2021-08-11 | 2025-06-25 | Oncohost Ltd | PREDICTING PATIENT RESPONSE |
| WO2024231293A1 (en) * | 2023-05-05 | 2024-11-14 | Euro-Celtique S.A. | Combinations for treating cancer |
| WO2024238811A2 (en) * | 2023-05-18 | 2024-11-21 | Avstera Therapeutics Corp. | Composition comprising hdac inhibitor and immune checkpoint inhibitor and methods for using the same |
| WO2025155922A1 (en) * | 2024-01-19 | 2025-07-24 | The Trustees Of Indiana University | Hdac3 inhibitors to treat arrhythmogenic cardiomyopathy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ600281A (en) | 2006-12-27 | 2013-03-28 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| US9987258B2 (en) * | 2014-04-06 | 2018-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase as a modulator of PDL1 expression and activity |
| CN107614011A (zh) | 2015-03-20 | 2018-01-19 | 欣达克斯制药公司 | Hdac抑制剂和抗pd‑1抗体联合用于癌症的治疗 |
| WO2017035453A1 (en) * | 2015-08-26 | 2017-03-02 | The Johns Hopkins University | Compositions and methods for treating solid tumors |
| KR102631377B1 (ko) | 2015-09-02 | 2024-01-29 | 신닥스 파마슈티컬스, 인크. | 조합 요법을 위한 환자의 선별 |
-
2017
- 2017-01-27 AU AU2017211383A patent/AU2017211383A1/en not_active Abandoned
- 2017-01-27 US US16/072,659 patent/US10813919B2/en active Active
- 2017-01-27 EP EP17704370.0A patent/EP3407913A1/en not_active Withdrawn
- 2017-01-27 WO PCT/US2017/015389 patent/WO2017132536A1/en not_active Ceased
- 2017-01-27 MX MX2018009247A patent/MX2018009247A/es unknown
- 2017-01-27 RU RU2018130831A patent/RU2018130831A/ru not_active Application Discontinuation
- 2017-01-27 CN CN201780020460.2A patent/CN108883179A/zh active Pending
- 2017-01-27 JP JP2018539087A patent/JP2019503386A/ja active Pending
- 2017-01-27 KR KR1020187024674A patent/KR20180104122A/ko not_active Withdrawn
- 2017-01-27 BR BR112018015291A patent/BR112018015291A2/pt not_active IP Right Cessation
- 2017-01-27 CA CA3013047A patent/CA3013047A1/en not_active Abandoned
-
2018
- 2018-07-24 IL IL260765A patent/IL260765A/en unknown
- 2018-07-27 ZA ZA2018/05066A patent/ZA201805066B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018130831A (ru) | 2020-03-02 |
| CA3013047A1 (en) | 2017-08-03 |
| MX2018009247A (es) | 2019-03-11 |
| ZA201805066B (en) | 2019-05-29 |
| EP3407913A1 (en) | 2018-12-05 |
| CN108883179A (zh) | 2018-11-23 |
| US20190030011A1 (en) | 2019-01-31 |
| US10813919B2 (en) | 2020-10-27 |
| JP2019503386A (ja) | 2019-02-07 |
| KR20180104122A (ko) | 2018-09-19 |
| WO2017132536A1 (en) | 2017-08-03 |
| IL260765A (en) | 2018-10-31 |
| RU2018130831A3 (enExample) | 2020-04-23 |
| AU2017211383A1 (en) | 2018-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018015291A2 (pt) | uso de inibidores de histona desacetilase para melhorar imunoterapias | |
| CY1123676T1 (el) | Συνθεσεις και μεθοδοι για την εσωτερικοποιηση ενζυμων | |
| CA2971734C (en) | Anti-pd-1 antibodies | |
| MX2020005477A (es) | Inmunoterapias con el uso de células efectoras potenciadas derivadas de ipsc. | |
| EA201790968A1 (ru) | Опосредуемая пептидом доставка направляемой рнк эндонуклеазы в клетки | |
| MX395342B (es) | Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. | |
| MX382624B (es) | Compuestos farmacéuticos. | |
| CU20150119A7 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| MX385750B (es) | Compuestos y métodos para la degradación mejorada de proteinas específicas. | |
| EA201992358A1 (ru) | Тканеселективная экспрессия трансгена | |
| EA201890278A1 (ru) | Антитела к pd-l1 | |
| PL3313991T3 (pl) | Modyfikowany czynnik ix oraz kompozycje, sposoby i zastosowania do transferu genów do komórek, narządów i tkanek | |
| EA201400772A1 (ru) | Варианты полипептидов ph20, композиции на их основе и их применение | |
| EA201592103A2 (ru) | Способы и композиции для усиления cd4+ регуляторных t-клеток | |
| MX382607B (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa. | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| EA201500394A1 (ru) | Ингибиторы деметилаз гистонов | |
| MD20150100A2 (ro) | Virusurile bolii de Newcastle şi utilizarea acestora | |
| BR112015032595A2 (pt) | inibidores de ido | |
| EA201900561A1 (ru) | Конъюгаты циклодекстрин-белок-лекарственное средство | |
| EA202090632A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| GT201400066A (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| MX2017016322A (es) | Metodos para tratar tumores de celulas epitelioides. | |
| CO6950477A2 (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| EA201890439A1 (ru) | ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2655 DE 23-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |